Afrezza Inhaled Insulin for Pediatric Diabetes

INHALE-1 (NCT04974528) reported in Dec 2024: mITT analysis met non-inferiority on HbA1c (0.370% vs 0.4% margin); ITT narrowly missed (0.435%) due to one non-adherent patient. Company and FDA treated result as positive—sBLA was accepted in 2026. Most reasonable adjudication of 'positive result on change in HbA1c' resolves YES, though ITT miss creates some ambiguity risk depending on resolution criteria.

Afrezza is an approved adult inhaled insulin with established efficacy; pediatric Phase 3 (INHALE-3-like) tests non-inferiority on HbA1c at 26 weeks vs basal-bolus. Non-inferiority endpoints have higher success rates than superiority, and prior adult data support glycemic control. However, pediatric trials face adherence and dosing-variability risks, and prior MNKD pediatric readouts have been mixed. Trial is completed; readout risk skews modestly positive.

Phase 3 completed pediatric study uses a standard 26-week HbA1c noninferiority endpoint. Adult Afrezza efficacy and objective glycemic endpoint support success, but pediatric dosing, inhaler technique/adherence, mixed T1/T2 population, and disclosure risk temper odds.

Phase 3 noninferiority on objective HbA1c is a favorable setup, and inhaled insulin has plausible efficacy with basal insulin. Pediatric dosing/adherence, mixed T1/T2 population, and no disclosed result despite completed status long after primary completion temper the odds.

Phase 3, completed, objective HbA1c endpoint and noninferiority at 26 weeks favor success for an insulin regimen. Pediatric/teen population, mixed T1/T2, adherence/dosing variability and inhaled-insulin tolerability add risk. Disclosure risk remains since completion is well past.

Phase 3 noninferiority trial on HbA1c at 26 weeks in pediatric T1/T2 diabetes using established inhaled insulin plus basal; typical success rate for such powered, sponsor-designed endpoints is 65-75%.

Phase 3 open-label noninferiority trial of Afrezza vs MDI in 4-17yo T1/T2 diabetes; primary endpoint HbA1c change at 26 weeks is standard, well-powered for NI margin of 0.4%; prior adult success and completed status on schedule support likely meeting NI.

Phase 3 completed trial of Afrezza + basal in pediatric T1/T2 diabetes; primary noninferiority endpoint on HbA1c change at 26 weeks. Adult efficacy data supportive, trial powered for success, no early stoppage signals, moderate pediatric delivery risk.

The INHALE-1 phase 3 trial evaluated Afrezza vs MDI in pediatric diabetes for HbA1c non-inferiority at 26 weeks. In Dec 2024, MannKind reported the strict ITT analysis missed the 0.4% margin (0.435%). However, a mITT analysis excluding one non-adherent outlier met the margin (0.370%). MannKind explicitly declared this established non-inferiority and met the primary endpoint. The FDA has since accepted the sBLA based on these results. Prediction markets typically follow the sponsor's headline declaration, making YES highly likely.

The INHALE-1 trial missed its prespecified primary ITT non-inferiority endpoint for HbA1c change (95% CI upper bound 0.435%, P=0.091 vs 0.4% margin). While the sponsor claimed success via a post-hoc modified ITT analysis excluding one outlier, independent medical publications correctly state the trial missed its primary endpoint. Prediction markets typically resolve based on the formal ITT.

Afrezza is an approved inhaled insulin. INHALE-1 results from Dec 2024 showed the ITT population missed the non-inferiority margin due to a single outlier. However, the modified ITT established non-inferiority, and MannKind announced the trial met its primary endpoint. Prediction markets typically resolve based on sponsor topline claims, making YES highly likely despite the ITT technicality.

Phase 3 noninferiority trial in pediatric diabetes, completed but results not yet public. Afrezza is approved for adults with similar efficacy; noninferiority design lowers bar. However, pediatric lung safety and adherence could pose risks. Base rate for such trials is moderately positive.

Phase 3 noninferiority trial in pediatric diabetes. Afrezza is approved in adults, reducing novel mechanism risk. Noninferiority design has lower bar than superiority. Completed status suggests no early termination for futility or safety. Pediatric adherence and inhalation technique are risks, but overall probability of success is moderately high.

Afrezza is approved for adults with noninferior HbA1c data. This pediatric trial uses same endpoint and noninferiority design. Completed trial likely has favorable results given established efficacy, though pediatric lung safety could be a risk. Probability of positive is moderately high.

Phase 3 non-inferiority trial of Afrezza in pediatric T1D/T2D. Afrezza is approved in adults; pediatric extension typically succeeds if non-inferiority margin is standard. However, inhaled delivery in kids may cause variability, and Afrezza has shown slightly weaker HbA1c reduction vs rapid analogs. Success is likely but not certain.

Afrezza already demonstrated noninferiority vs injected insulin in adults. Pediatric noninferiority on HbA1c is a reasonable extension, though pediatric glycemic control is more variable. Phase 3 completion suggests interim signals were acceptable. Noninferiority design lowers the efficacy bar vs superiority. Main risk is dosing consistency in younger children with inhaled delivery.

Noninferiority design helps, and Afrezza works in adults, but pediatric HbA1c control is harder and inhaled compliance uncertain. Trial completed ~20 months ago with no announced positive results—a negative signal. Modest lean NO on delayed disclosure bias and pediatric execution risk.

Afrezza has established efficacy in adults. Pediatric T1D trials typically show non-inferiority for rapid-acting insulins vs standard care on HbA1c. MannKind has strong incentive to succeed. Primary completion date passed, suggesting data exists. Historical FDA approvals for similar mechanisms support positive outcome likelihood despite pediatric specific challenges.

Afrezza has established efficacy in adults. Pediatric T1D trials typically show HbA1c non-inferiority vs injectable insulin if adherence is managed. MannKind has strong incentive to succeed in this expansion. Primary endpoint is standard. Completion date passed, suggesting data exists. Historical precedents for inhaled insulin in pediatrics are mixed but Afrezza's profile is favorable.

Afrezza has established efficacy in adults. Pediatric T1D trials typically show HbA1c non-inferiority vs injected rapid-acting insulin if adherence is managed. MannKind has strong incentive to succeed. Primary endpoint is standard. Completion date passed, implying data exists. Historical precedents for inhaled insulin in peds are mixed but Afrezza's profile is favorable.

The trial is a Phase 3, completed study of Afrezza inhaled insulin in children and teens, using HbA1c change at 26 weeks as a non‑inferiority primary endpoint. Inhaled insulin has shown comparable efficacy to subcutaneous insulin in adults, but pediatric data are limited and adherence can be variable. The design modestly favors a positive outcome, yet safety and device‑use uncertainties lower confidence, yielding a modestly above‑50 % chance of success.

Phase‑3 non‑inferiority trial in children using inhaled insulin, a modality with limited pediatric data and variable lung absorption. Prior adult studies showed mixed efficacy, raising risk of failing the HbA1c target. No safety flags appear, but the novel population suggests a modest chance of success.

Phase‑3 completed, primary endpoint is non‑inferiority HbA1c at 26 weeks. Inhaled insulin has shown comparable efficacy to injected insulin in adult trials, and pediatric pharmacodynamics appear similar, but lung‑capacity variability and adherence in children add risk. Overall modest chance of meeting the non‑inferiority margin.

Phase 3 completed with -598 days past primary completion, suggesting data known. Pediatric HbA1c noninferiority endpoint with inhaled insulin is challenging due to dosing variability and adherence in children. However, Afrezza is approved in adults with established glycemic efficacy. Completed status without public disclosure of failure suggests possible positive outcome, though pediatric noninferiority margins may be lenient. Disclosure risk moderate given sponsor silence.

Phase 3 pediatric diabetes trial with HbA1c noninferiority endpoint completed Oct 2024 but no results disclosed 596+ days later. Afrezza has known adult approval but pediatric inhalation compliance is challenging. Extended silence suggests potential negative or borderline results requiring negotiation with FDA. Sponsor MNKD has disclosure risk history.

Afrezza has mixed adult data with prior FDA rejection for labeling concerns. Pediatric noninferiority HbA1c trials are challenging; inhaled insulin faces adherence and dosing variability risks. Completed status without announced positive topline suggests potential underperformance or regulatory caution in disclosure. Noninferiority margin may be tight given pediatric glycemic variability.

Phase 3 completed noninferiority trial of Afrezza (already FDA-approved adult insulin) tested in pediatric diabetes with HbA1c endpoint. Noninferiority design lowers bar versus superiority. Prior adult data supports mechanism. Completed status suggests operational success. New pediatric indication likely has reasonable efficacy profile.

Trial completed Oct 2024 with 62% YES pricing suggesting positive but uncertain outcome. Phase 3 noninferiority design for pediatric label expansion of already-approved Afrezza. HbA1c endpoint is objective and clinically validated. Prior adult approval provides favorable prior probability. Market pricing at 0.62 implies moderate confidence in success, consistent with intrinsic assessment.

Afrezza is approved for adults; pediatric extension leverages established efficacy. Phase 3 completion with HbA1c endpoint (standard, validated) supports positive outcome. Non-inferiority design and prior adult data increase success probability.